Next Article in Journal
Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives
Next Article in Special Issue
The Hippo Pathway: Immunity and Cancer
Previous Article in Journal
Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
Previous Article in Special Issue
Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors
Open AccessFeature PaperReview

Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma

Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
Department of Cancer Genetics, Nagoya University Graduate School of Medicine, Nagoya 464-8681, Japan
Cancers 2018, 10(4), 90;
Received: 28 February 2018 / Revised: 20 March 2018 / Accepted: 21 March 2018 / Published: 22 March 2018
Malignant mesothelioma (MM) constitutes a very aggressive tumor that arises from the pleural or peritoneal cavities and is highly refractory to conventional therapies. Several key genetic alterations are associated with the development and progression of MM including mutations of the CDKN2A/ARF, NF2, and BAP1 tumor-suppressor genes. Notably, activating oncogene mutations are very rare; thus, it is difficult to develop effective inhibitors to treat MM. The NF2 gene encodes merlin, a protein that regulates multiple cell-signaling cascades including the Hippo pathway. MMs also exhibit inactivation of Hippo pathway components including LATS1/2, strongly suggesting that merlin-Hippo pathway dysregulation plays a key role in the development and progression of MM. Furthermore, Hippo pathway inactivation has been shown to result in constitutive activation of the YAP1/TAZ transcriptional coactivators, thereby conferring malignant phenotypes to mesothelial cells. Critical YAP1/TAZ target genes, including prooncogenic CCDN1 and CTGF, have also been shown to enhance the malignant phenotypes of MM cells. Together, these data indicate the Hippo pathway as a therapeutic target for the treatment of MM, and support the development of new strategies to effectively target the activation status of YAP1/TAZ as a promising therapeutic modality for this formidable disease. View Full-Text
Keywords: malignant mesothelioma; NF2; Hippo pathway; YAP1/TAZ malignant mesothelioma; NF2; Hippo pathway; YAP1/TAZ
Show Figures

Figure 1

MDPI and ACS Style

Sekido, Y. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Cancers 2018, 10, 90.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop